1 Wall Street Analyst Raises Editas Medicine's Price Target by 45%. Here's Why She's Right. [Yahoo! Finance]
Editas Medicine, Inc. (EDIT)
Last editas medicine, inc. earnings: 2/26 04:02 pm
Check Earnings Report
US:NASDAQ Investor Relations:
ir.editasmedicine.com
Company Research
Source: Yahoo! Finance
to reach $16 -- an increase of 45% over her prior estimate -- there's a clear consensus about the stock forming on Wall Street. Based on Semenkow's price target, which is effectively the same as the consensus average price target across analysts following the stock, Editas Medicine is looking at a 70% bump. It could happen. Here's why. This company just got a huge break from regulators Per Editas' fourth-quarter earnings report, the Food and Drug Administration (FDA) is now on board with the company's proposal to run its lead program, reni-cel, as a combined phase 1/2/3 clinical trial. Reni-cel is a gene therapy being developed to treat rare blood disorders sickle cell disease (SCD) and beta thalassemia, and it's intended to be curative or near-curative, just like the therapies recently commercialized by other gene editing companies like CRISPR Therapeutics and Bluebird Bio Before the agreement with regulators, the program was in phase 1/2 clinical trials, and it had been repo
Show less
Read more
Impact Snapshot
Event Time:
EDIT
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EDIT alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EDIT alerts
High impacting Editas Medicine, Inc. news events
Weekly update
A roundup of the hottest topics
EDIT
News
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual Meeting [Yahoo! Finance]Yahoo! Finance
- Editas Medicine to Present Pre-clinical Data Demonstrating Progression of in vivo Medicines Pipeline at the American Society of Gene and Cell Therapy Annual MeetingGlobeNewswire
- Dr. Chi Li Joins Curevo Vaccine as Chief Regulatory Officer [Yahoo! Finance]Yahoo! Finance
- Why Is Editas (EDIT) Down 26.2% Since Last Earnings Report? [Yahoo! Finance]Yahoo! Finance
- Vor Bio Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Company Update [Yahoo! Finance]Yahoo! Finance
EDIT
Earnings
- 2/28/24 - Beat
EDIT
Sec Filings
- 4/16/24 - Form DEFA14A
- 4/16/24 - Form DEF
- 4/10/24 - Form SC
- EDIT's page on the SEC website